Ultragenyx Pharmaceutical Inc.
Edit

Ultragenyx Pharmaceutical Inc.

https://www.ultragenyx.com/
Last activity: 10.09.2024
Active
Categories: BioTechCareFutureHealthTechLearnMarketMedtechMovingProductScience
At Ultragenyx, we fundamentally believe that taking real impactful action to care for the needs of patients and our people is always the right thing to do. To achieve this goal, our vision is to lead the future of rare disease medicine. For us, this means going where other biopharma companies won’t go – challenging the status quo and creating a new model that advances our field so more patients and caregivers can benefit from life-changing treatments. We do this by following the science, applying a novel rapid development approach, making innovative medicines at fair and reasonable prices, and creating a collaborative ecosystem to reach patients in ways that are most meaningful for them.

Our commitment and care for patients extends to our people, so culture is an essential cornerstone for Ultragenyx. We remain continuously focused on creating a supportive and inclusive environment of profound learning and growth – so employees can thrive in all areas of their lives, in and outside of work. Ultimately, we want to be an organization where we would be proud for our family, friends and children to work.

If you want to have a meaningful impact, do the best work of your career, and grow a lot, both professionally and personally, come join our team. During the COVID-19 Outbreak, we are committed to our hiring process. The health and safety of our employees and prospective employees take priority which means at this time our approach will include video discussions, interviews, and onboarding.
Followers
43.21K
Website visits
63.5K /mo.
Mentions
41
Location: United States, California, Novato
Employees: 501-1000
Total raised: $45M
Founded date: 2010

Investors 5

Funding Rounds 1

DateSeriesAmountInvestors
20.06.2011Series A$45M-

Mentions in press and media 41

DateTitleDescription
12.09.2024The Hidden Struggles of X-Linked Hypophosphatemia: A Call for Awareness and ActionX-linked hypophosphatemia (XLH) is a name that may not ring a bell for many. Yet, for those affected, it’s a daily battle. A recent analysis from the XLH Disease Monitoring Program (DMP) sheds light on the harsh realities faced by adults li...
10.09.2024New Analysis Demonstrates Impaired Work Productivity and Increased Unemployment Rates in Adults with X-linked Hypophosphatemia (XLH)Findings from XLH Disease Monitoring Program (DMP) published in Journal of Bone and Mineral Research (JBMR Plus) DMP is a global effort, supported by Kyowa Kirin, to advance understanding and care of XLH through real-world research Addition...
09.09.2024More space for healthtech start-ups on the Novartis Campus Digitalisation is one of the megatrends in the healthcare sector. It not only promises greater efficiency, but also new possibilities in diagnostics and therapeutics. As this field requires expertise that traditional healthcare companies o...
22.08.2024Global Genes' Annual Week in RARE Event Heading to Kansas CityGlobal Genes Global Genes is taking Week In RARE on the road to Kansas City, after having hosted this annual event in California for over 12 years. Moving the location annually will help make the event more accessible and equitable to the g...
05.06.2023Ultragenyx and Mereo BioPharma Announce Positive Data from the Ongoing Phase 2/3 Orbit Study of Setrusumab (UX143) in Osteogenesis Imperfecta (OI)/EIN News/ -- Pediatric data show substantial induction of bone production in 1 week and a large increase in bone formation within 3 months of initiating monthly setrusumab treatment Phase 3 sites beginning to screen patients Conference cal...
06.01.2023Ultragenyx Reports Preliminary 2022 Revenue; Guidance for 2023 Revenue and Cash Usage; Pipeline Updates and 2023 MilestonesPreliminary 2022 Total Product Revenue of $352 million to $356 million, Crysvita® Revenue in Ultragenyx Territories1 of $257 million to $258 million and Dojolvi® revenue of $55 million to $56 million 2023 expected Total Product Revenue guid...
09.09.2022Ultragenyx and Mereo BioPharma to Present Setrusumab Data Update at ASBMRNOVATO, Calif. and MOUNTAIN VIEW, Calif. and LONDON, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), (“Ultragenyx”), a biopharmaceutical company focused on the development and commercialization of novel pro...
11.02.2022Ultragenyx Pharmaceutical : Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update - Form 8-KUltragenyx Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update 2021 total revenue of $351.4 million and 2021 Crysvita® revenue in Ultragenyx territories1 of $192.6 million 2022 Crysvita revenue in Ultragenyx ter...
11.02.2022Ultragenyx Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update2021 total revenue of $351.4 million and 2021 Crysvita® revenue in Ultragenyx territories1 of $192.6 million 2022 Crysvita revenue in Ultragenyx territories guidance of $250 million to $260 million and Dojolvi revenue of $55 million to $65 ...
05.01.2022GeneTx and Ultragenyx Provide Preliminary Update on Phase 1/2 Clinical Study of GTX-102 in Canada and U.K. Patients with Angelman SyndromeSARASOTA, Fla. and NOVATO, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- GeneTx Biotherapeutics LLC and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), companies partnered in the development of GTX-102, an investigational treatment for Angelman ...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In